Jazz Pharmaceuticals
JAZZ
230.26
-6.19
-2.62%
Jazz Pharmaceuticals
US · JAZZ
#1123 by market cap
Listed 1970
230.26
-6.19
-2.62%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Quant vs Street three independent views, side by side
StockVane factor grade
B-
Momentum strategy signal
Hold
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 1 upgrade vs 0 downgrades among tracked analyst rating changes.
- Most recent: UBS moved from Hold to Buy on 2026-05-19.
Analyst consensus 16 analysts
Buy
Avg price target 307.13 +33.4%
Price target rangecurrent 230.26
Low275.00
Avg307.13
High337.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-16 | Needham | -- | Buy | 308.00 |
| 2026-11-13 | UBS | -- | Buy | 326.00 |
| 2026-11-13 | Morgan Stanley | -- | Buy | 324.00 |
| 2026-11-12 | Piper Sandler | -- | Buy | 330.00 |
| 2026-11-03 | TD Cowen | -- | Buy | 300.00 |
| 2026-11-03 | CCORF | -- | Buy | 300.00 |
| 2026-11-03 | Wells Fargo | -- | Buy | 300.00 |
| 2026-11-03 | Piper Sandler | -- | Buy | 310.00 |
| 2026-11-03 | Morgan Stanley | -- | Buy | 319.00 |
| 2026-11-03 | Stifel | -- | Buy | 275.00 |
| 2026-11-03 | Barclays | -- | Buy | 275.00 |
| 2026-11-03 | RBC Capital | -- | Buy | 305.00 |
| 2026-11-03 | J.P. Morgan | -- | Buy | 310.00 |
| 2026-11-02 | Wells Fargo | -- | Buy | 300.00 |
| 2026-11-02 | BofA Securities | -- | Buy | 313.00 |
| 2026-11-02 | Morgan Stanley | -- | Buy | 314.00 |
| 2026-11-02 | Citi | -- | Buy | 325.00 |
| 2026-10-28 | UBS | -- | Buy | 337.00 |
| 2026-10-28 | J.P. Morgan | -- | Buy | 300.00 |
| 2026-10-27 | Citi | -- | Buy | 325.00 |
| 2026-10-21 | Morgan Stanley | -- | Buy | 314.00 |
| 2026-10-16 | Needham | -- | Buy | 310.00 |
| 2026-10-15 | Citi | -- | Buy | 325.00 |
| 2026-10-13 | Barclays | -- | Buy | 271.00 |
| 2026-10-09 | BofA Securities | -- | Buy | 313.00 |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-05-19 | UBS | Hold → Buy | 307.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-02 | After close | ±7.69% | +7.13% (in line) |
| 2026/Q2 | 2026-08-03 | After close | ±6.48% | +3.99% (in line) |
| 2026/Q1 | 2026-05-05 | After close | ±6.19% | +7.68% (beat) |
| 2025/Q4 | 2026-02-24 | After close | ±7.84% | +13.23% (beat) |
| 2025/Q3 | 2025-11-05 | After close | ±7.81% | -2.31% (in line) |
| 2025/Q2 | 2025-08-05 | After close | ±10.58% | -6.42% (in line) |
| 2025/Q1 | 2025-05-06 | After close | ±11.47% | -8.75% (in line) |
| 2024/Q4 | 2025-02-25 | After close | ±8.47% | +3.22% (in line) |
| 2024/Q3 | 2024-11-06 | After close | ±7.79% | +6.75% (in line) |
| 2024/Q2 | 2024-07-31 | After close | ±9.90% | +3.75% (in line) |
| 2024/Q1 | 2024-05-01 | After close | ±8.33% | -0.92% (in line) |
| 2023/Q4 | 2024-02-28 | After close | ±8.73% | -8.33% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 20:02:26 · For reference only, not investment advice and not tailored to your situation.
Jazz Pharmaceuticals discussion 0 comments